Recent investigations have centered on the overlap of GLP-1|glucose-dependent insulinotropic polypeptide|GCGR stimulant therapies and dopaminergic neurotransmission. While GIP stimulators are commonly employed for addressing type 2 T2DM, their emerging consequences on reward circuits, specifically influenced by dopaminergic pathways, are attract… Read More